Question
Does Tofacitinib Increase the Risk of Venous Thromboembolism in Patients with RA?
Conclusion
Recently, a link between venous thromboembolism (VTE) and Janus Kinase (JAK) inhibitors has emerged, causing the FDA to recommend a black box label for tofacitinib in 2019. New research, however, suggests that tofacitinib had similarly infrequent cases of VTE (<1 per 100) when compared with tumor necrosis factor inhibitors (TNFIs).
Recent Posts
- Question of the Week
- Is In-person and remote physical therapy are equally effective for Chronic Knee Pain?
- The risk of breast cancer overdiagnosis is high for older women
- Severe hypocalcemia with denosumab therapy in dialysis-treated patients
- Sarilumab increases remission, decreases steroid dose in polymyalgia rheumatica taper, but at a high cost (SAPHYR)
Leave A Comment